Notify me when Pontifax Management 4 G.P. (2015) Ltd. files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CLYM | Climb Bio, Inc. | Common Stock, par value $0.0001 per share | 7.7% | $12.9M | 5.21M | Pontifax VI G.P. L.P. | Jun 27, 2024 | ||
| LB Pharmaceuticals Inc | Common Stock, $0.0001 par value per share | 6.3% | 1.41M | Pontifax Management 4 G.P. (2015) Ltd. | Sep 12, 2025 | ||||
| KROS | Keros Therapeutics, Inc. | Common Stock, Par Value $0.0001 Per Share | 0% | $0 | -$75.7M | 0 | -100% | Pontifax Management 4 GP (2015) Ltd. | Oct 15, 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Date Filed |
|---|